The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer

Rebecca R. Pharaon; Yan Xing; Mark Agulnik; Victoria M. Villaflor

doi:10.3389/fonc.2021.649963

The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer

Rebecca R. Pharaon, Yan Xing, Mark Agulnik, Victoria M. Villaflor

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

A subset of head and neck cancers arising in the oropharynx and the nasopharynx are associated with human papillomavirus or Epstein–Barr virus. Unfortunately, limited treatment options exist once patients develop recurrent or metastatic disease in these cancers. Interest has risen in utilizing novel strategies including combination immune checkpoint inhibitors, vaccines, and adoptive cellular therapy, to improve treatment response and outcomes. Several ongoing studies are investigating the potential to overcome resistance to standard of care chemoradiation therapy with monotherapy or combination immunotherapy strategies in these viral-associated head and neck cancers.

Original language	English (US)
Article number	649963
Journal	Frontiers in Oncology
Volume	11
DOIs	https://doi.org/10.3389/fonc.2021.649963
State	Published - Jul 16 2021

Keywords

Epstein–Barr virus
head and neck cancer
human papillomavirus
immunotherapy
nasopharyngeal carcinoma
oropharyngeal squamous cell carcinoma
viral-associated cancers

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3389/fonc.2021.649963

Cite this

@article{32dbd665f7a6482a801bf60ff1a7200b,

title = "The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer",

abstract = "A subset of head and neck cancers arising in the oropharynx and the nasopharynx are associated with human papillomavirus or Epstein–Barr virus. Unfortunately, limited treatment options exist once patients develop recurrent or metastatic disease in these cancers. Interest has risen in utilizing novel strategies including combination immune checkpoint inhibitors, vaccines, and adoptive cellular therapy, to improve treatment response and outcomes. Several ongoing studies are investigating the potential to overcome resistance to standard of care chemoradiation therapy with monotherapy or combination immunotherapy strategies in these viral-associated head and neck cancers.",

keywords = "Epstein–Barr virus, head and neck cancer, human papillomavirus, immunotherapy, nasopharyngeal carcinoma, oropharyngeal squamous cell carcinoma, viral-associated cancers",

author = "Pharaon, {Rebecca R.} and Yan Xing and Mark Agulnik and Villaflor, {Victoria M.}",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Pharaon, Xing, Agulnik and Villaflor.",

year = "2021",

month = jul,

day = "16",

doi = "10.3389/fonc.2021.649963",

language = "English (US)",

volume = "11",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer

AU - Pharaon, Rebecca R.

AU - Xing, Yan

AU - Agulnik, Mark

AU - Villaflor, Victoria M.

PY - 2021/7/16

Y1 - 2021/7/16

N2 - A subset of head and neck cancers arising in the oropharynx and the nasopharynx are associated with human papillomavirus or Epstein–Barr virus. Unfortunately, limited treatment options exist once patients develop recurrent or metastatic disease in these cancers. Interest has risen in utilizing novel strategies including combination immune checkpoint inhibitors, vaccines, and adoptive cellular therapy, to improve treatment response and outcomes. Several ongoing studies are investigating the potential to overcome resistance to standard of care chemoradiation therapy with monotherapy or combination immunotherapy strategies in these viral-associated head and neck cancers.

AB - A subset of head and neck cancers arising in the oropharynx and the nasopharynx are associated with human papillomavirus or Epstein–Barr virus. Unfortunately, limited treatment options exist once patients develop recurrent or metastatic disease in these cancers. Interest has risen in utilizing novel strategies including combination immune checkpoint inhibitors, vaccines, and adoptive cellular therapy, to improve treatment response and outcomes. Several ongoing studies are investigating the potential to overcome resistance to standard of care chemoradiation therapy with monotherapy or combination immunotherapy strategies in these viral-associated head and neck cancers.

KW - Epstein–Barr virus

KW - head and neck cancer

KW - human papillomavirus

KW - immunotherapy

KW - nasopharyngeal carcinoma

KW - oropharyngeal squamous cell carcinoma

KW - viral-associated cancers

UR - http://www.scopus.com/inward/record.url?scp=85111574387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111574387&partnerID=8YFLogxK

U2 - 10.3389/fonc.2021.649963

DO - 10.3389/fonc.2021.649963

M3 - Review article

AN - SCOPUS:85111574387

VL - 11

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 649963

ER -

The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this